Apollo Hospitals Enterprise Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Resilient quarter despite Bangladesh drag: Consolidated revenue crossed INR 20,000 cr for FY25, with double-digit growth across all three verticals, even as the Bangladesh crisis shaved INR 100 cr from revenue and ~50 bps from EBITDA margin.
• HealthCo turns the corner on profitability: The platform posted its third straight profitable quarter and management laid out a clear bridge to a 7%+ EBITDA margin by FY27, driven by tapering ESOP costs, digital breakeven, and offline pharmacy expansion.
• Hospital margins defended through expansion: Management expects to hold ~24% EBITDA margins in FY26 despite a 140 bps headwind from new hospitals, bridged by 80 bps in cost efficiencies and 60 bps from revenue-mix improvements.
• 24/7 digital platform approaching breakeven: The business is on track for cash breakeven by Q3/Q4 FY26, with operating expenses set to decline 15–20% and EBITDA margins targeted at 17–18% for the year.
• What to watch next quarter: Whether the Bangladesh headwind truly abates or is merely mitigated, the pace of new hospital commissioning (Pune, Kolkata, Defense Colony, Sarjapur), and the trajectory of the newly launched insurance corporate agency.

Bangladesh Impact & Mitigation

• Full-year toll: The crisis cost Apollo INR 100 cr in revenue (1.5% of consolidated) and approximately 50 bps of EBITDA margin, with the impact most pronounced in Q3 and Q4.
• Mitigation strategy is working: Apollo pivoted to other international markets, which increased substantially YoY, while improving local market share and driving higher contribution from CONGO specialties (cardiology, oncology, neurosciences, gastroenterology, orthopedics). Quaternary care hospitals also pulled patients from surrounding markets.
• No explicit return forecast: Management declined to confirm whether Bangladesh revenue returns in FY26, instead emphasizing that the mitigation plan is in place and the growth trajectory remains intact.

Akhileswaran: "Clearly, the Bangladesh business has for the whole year impacted our revenues by at least INR 100 crore and which is 1.5% for the full year. And somewhere, if you look at our EBITDA margin also, had Bangladesh been there with us, we would have been in line with what we had guided to you of at least closer to another 50 basis points on the EBITDA as well."

Hospital Margin Bridge & Expansion

• The 140 bps headwind: New hospitals coming online in FY26 (Pune, Kolkata, Defense Colony, Sarjapur Stage 1) are expected to dilute margins by an estimated 140 basis points.
• The offset is two-pronged: 80 bps from cost improvements (technology-driven workforce productivity, materials cost management, sustainability gains) and 60 bps from revenue enhancements (better payer mix, higher case complexity, improved ARPOB, higher occupancy).
• Commissioning timeline: Pune, Kolkata, Defense Colony, and the first Sarjapur acquisition (200 beds) operationalize by Q3; significant additional bed additions arrive in Q4. The Secunderabad brownfield expansion carries a corrected project cost of INR 54 crore, not the INR 545 crore initially shown on a slide.
• Bangalore and Hyderabad scaling: Sarjapur will add 700 beds in two stages (200-bed acquisition plus 500-bed greenfield), taking Bangalore to 1,500 beds. Hyderabad expansions at Jubilee Hills, Secunderabad, and planned Gachibowli will also reach 1,500 beds.

Suneeta Reddy: "About 140 basis points estimate is what we see, and 80 basis points improvement will come from costs. The balance 60 basis points will come from improved revenues, because of the initiatives that we are taking within the hospital from improving the payer mix to complexity to improving ARPOB, and higher occupancy."

HealthCo: The Path to 7%+ Margins

• FY25 blended margin was 3.2% but the underlying picture is stronger: excluding ESOP costs and 24/7 operating losses, the margin would have been 6.4%.
• The bridge to 7%+ in FY27: ESOP costs taper to one-third from FY27 (FY26: ~INR 100 cr), digital losses reach breakeven by Q3/Q4 FY26, offline pharmacy margins expand ~100 bps from 7.4%, and Keimed margins improve 40–50 bps after a one-time dip from acquisition-related legal fees and subsidiary costs.
• Revenue visibility: HealthCo combined revenue is targeted at ~INR 24,000 cr for FY27, with the run rate crossing INR 25,000 cr by Q3/Q4 FY27.
• Pharmacy growth re-accelerating: Front-end pharmacy growth is expected upwards of 20% in FY26 after a prior-year slowdown from election-related approval delays and late store openings. Rx growth was already 23–24%, with the softness concentrated in FMCG and health essentials.
• Store expansion continues: Apollo plans 375–500 more pharmacy outlets, maintaining a pace of roughly one per day, with a long-term market share target of 20% (from ~8% currently).

Sanjiv Gupta: "If I remove these two things, if I assume these two things even today and remove these losses and the ESOP cost, the new number that comes for the EBITDA percentage is 6.4%. So that means clearly, once the digital losses are off, the ESOP cost is rationalized to a lower number, we should be seeing blended with offline pharma and Keimed to be in the range of about 6.5% to 7%."

24/7 Digital Platform: Breakeven in Sight

• Cash breakeven targeted for Q3/Q4 FY26, with operating expenses declining 15–20% from ~INR 480 cr in FY25 to INR 400–425 cr in FY26. Beyond that, expenses will not fall further as a certain base is required to run the business.
• EBITDA margin jump to 17–18% in FY26 is driven by four levers: scaling the high-margin insurance vertical, app monetization with pharma companies (digital inventory for FMCG/OTC brands), reduced discounts through bank partnerships on card payments, and improved margins on Pharmacy, Diagnostics, and Consultations from scale.
• The 19-minute delivery proposition launched in the top 6 cities already contributes ~30% of total GMV and will extend to the next 10 cities. GMV-to-revenue conversion is targeted at 45–47% in FY26.
• Quick commerce competition: Management acknowledged the space but pushed back on partnership offers that would relegate Apollo to a back-office function, noting that Keimed already fills that role. Online pharmacy mix is 80% Rx medicines, insulating it somewhat from FMCG-focused quick commerce.

Balakrishnan: "We have received multiple offers, but we believe that it is not in the best interest of what we are trying to put forward... that basically relegates us to a back office a function, which one of our group companies, Keimed is already doing. So that's something which will not work."

Diagnostics & Clinics: Reset Complete

• Diagnostics slowdown was deliberate: The YoY deceleration came from resetting the franchisee business model (pricing and commission changes) to build a more sustainable and profitable base. That work is now complete, and high-teens growth is expected starting Q1 FY26.
• Margin ambition: The diagnostics business targets a 20% EBITDA margin, described as "a couple of years away," with FY26 margin growth of 2–3%.
• Apollo Clinics positioned as a unique primary care model: Management described it as the only model in India built around GPs and select specialists focused on primary care. Sharp improvement in Specialty Clinics was driven by working with hospitals to drive ProHealth and specialty checks.

Suneeta Reddy: "This is probably the only conceptually clinics that are created with GPs and some specialists that will look after primary care. Probably the only model in India that has this primary care focus."

New Ventures: Insurance & Other Updates

• Insurance corporate agency launched April 1: The business became a full-fledged corporate agent, with numbers already doubling versus the prior quarter. Q1 FY26 topline is expected at INR 6–7 cr, with a monthly exit target of INR 8–10 cr and breakeven within the year. Four more insurance partners are expected to be operational before June.
• SBI Cards co-branded card launched this month, aimed at driving sustainable business on pharmacy and diagnostics.
• Keimed merger progressing: The process is on a 15-month timeline.
• ESOP plan approved: The board has cleared an ESOP plan for senior employees and doctors; implementation details and financial impact will be shared next quarter.
• Apollo Cradle expansion: A new flagship Cradle Royale was inaugurated in Electronic City, Bangalore, with a PICU setup. The pediatric mix is expected to grow ~10% in the coming year.

Guidance & Commitments

Key Metrics